<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263236</url>
  </required_header>
  <id_info>
    <org_study_id>14095</org_study_id>
    <secondary_id>I5J-MC-NOAA</secondary_id>
    <nct_id>NCT01263236</nct_id>
  </id_info>
  <brief_title>A Study of LY2940094 in Major Depressive Disorder</brief_title>
  <official_title>A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackThorn Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlackThorn Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of ascending single&#xD;
      and multiple oral doses of LY2940094 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinically significant effects</measure>
    <time_frame>Baseline to study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, maximal concentration (Cmax)- single dose</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- single dose</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, maximal concentration (Cmax) - multiple dose</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours postdose on day 1, predose on days 2-6, predose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose on day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LY2940094, area under the concentration-time curve (AUC)- multiple dose</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours postdose on day 1, predose on days 2-6, predose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 hours postdose on day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>LY2940094 - single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 2-800 milligram (mg) LY2940094</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2940094 - multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose of 2-200 mg LY2940094 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose or daily oral dose for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2940094</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2940094 - multiple dose</arm_group_label>
    <arm_group_label>LY2940094 - single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males of any ethnic origin.&#xD;
&#xD;
          -  Have a body mass index (BMI) between 19.0 and 30.0 kilogram/square meter (kg/mÂ²),&#xD;
             inclusive.&#xD;
&#xD;
          -  Must be in good health, as determined by a medical history, physical examination,&#xD;
             12-lead electrocardiogram (ECG) and clinical laboratory evaluations.&#xD;
&#xD;
          -  Have a calculated creatinine clearance of greater than 70 milliliter/minute (mL/min).&#xD;
&#xD;
          -  Have venous access sufficient to allow blood sampling as per the protocol.&#xD;
&#xD;
          -  Will have given their written informed consent to participate in the study and to&#xD;
             abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male subjects who are not, or whose partners are not willing to use appropriate&#xD;
             contraception from the time of the first dose until 3 months after the final dosing&#xD;
             occasion.&#xD;
&#xD;
          -  Have received any prescribed systemic or topical medication within 14 days of the&#xD;
             first dose administration&#xD;
&#xD;
          -  Have used any non-prescribed systemic or topical medication (including herbal&#xD;
             remedies) within 7 days of the first dose administration (with the exception of&#xD;
             vitamin/mineral supplements) unless in the opinion of the Investigator the medication&#xD;
             will not interfere with the study procedures or compromise safety.&#xD;
&#xD;
          -  Have received any medications, including St John's Wort, known to chronically alter&#xD;
             drug absorption or elimination processes within 30 days of the first dose&#xD;
             administration&#xD;
&#xD;
          -  Currently enrolled in, have completed or discontinued within the last 30 days from, a&#xD;
             clinical trial involving an investigational product or are concurrently enrolled in&#xD;
             any other type of medical research judged not to be scientifically or medically&#xD;
             compatible with this study.&#xD;
&#xD;
          -  Have donated or lost 50 to 499 milliliter (mL) of whole blood within 30 days, or more&#xD;
             than 499 milliliter (mL) whole blood within 56 days preceding first dose&#xD;
             administration.&#xD;
&#xD;
          -  Have a significant history of drug allergy as determined by the Investigator.&#xD;
&#xD;
          -  Have any clinically significant allergic disease (excluding non-active hay fever), or&#xD;
             any known allergy to LY2940094 or excipients as determined by the Investigator.&#xD;
&#xD;
          -  Have a semi-reclined blood pressure and pulse rate higher than 130/90 millimeters of&#xD;
             mercury (mmHg) and 100 beats per minute (bpm), respectively, or lower than 90/50&#xD;
             millimeters of mercury (mmHg) and 40 beats per minute (bpm), respectively.&#xD;
&#xD;
          -  Consume more than 28 units of alcohol per week or who have a significant history of&#xD;
             alcoholism or drug/chemical abuse/dependence as determined by the Investigator.&#xD;
&#xD;
          -  Have a positive urine drug screen or alcohol breath test result that indicates&#xD;
             substance abuse at screening or at admission to any treatment period.&#xD;
&#xD;
          -  Smoke more than 10 cigarettes or the equivalent in tobacco per day and willing to&#xD;
             avoid smoking for durations of at least 10 hours.&#xD;
&#xD;
          -  With, or with a history of, any clinically significant neurological, gastrointestinal,&#xD;
             renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine,&#xD;
             hematological or other major disorders as determined by the Investigator.&#xD;
&#xD;
          -  Have had a clinically significant illness within 4 weeks of the start of dose&#xD;
             administration as determined by the Investigator.&#xD;
&#xD;
          -  Have serum hepatitis, or who are carriers of the hepatitis B surface antigen (HBsAg)&#xD;
             or hepatitis C antibody, or who have a positive result to the test for human&#xD;
             immunodeficiency virus (HIV) antibodies.&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risk of participating in the study. In addition, subjects&#xD;
             with the following findings will be excluded:&#xD;
&#xD;
               -  Confirmed Bazett's corrected QT (QTcB) interval greater than 450 millisecond&#xD;
                  (msec) in 2 of 3 electrocardiograms (ECGs).&#xD;
&#xD;
               -  Bundle branch blocks and other conduction abnormalities (including 2nd or 3rd&#xD;
                  degree Atrioventricular block, complete left bundle branch block, complete right&#xD;
                  bundle branch block or Wolffe-Parkinson-White Syndrome, defined as PR less than&#xD;
                  110 milliseconds (msec),confirmed by a repeat electrocardiogram [ECG]) other than&#xD;
                  mild first-degree atrioventricular block (AV) block.&#xD;
&#xD;
               -  Irregular rhythms other than sinus arrhythmia or occasional rare supraventricular&#xD;
                  ectopic beats.&#xD;
&#xD;
               -  History of unexplained syncope.&#xD;
&#xD;
               -  Family history of unexplained syncope or sudden death due to long QT syndrome.&#xD;
&#xD;
               -  T wave configurations are not of adequate quality for assessing QTc intervals.&#xD;
&#xD;
          -  Have previously completed or been withdrawn from this study.&#xD;
&#xD;
          -  Taking any excluded medications that cannot be discontinued at Screening.&#xD;
&#xD;
          -  Have a personal or family history of recurrent seizures or complicated febrile&#xD;
             seizures.&#xD;
&#xD;
          -  Have a history of significant brain trauma.&#xD;
&#xD;
          -  Have epileptiform activity on baseline electroencephalogram (EEG).&#xD;
&#xD;
        The following exclusion criteria apply only to those subjects enrolling in the part of the&#xD;
        study involving lumbar puncture (LP) procedures&#xD;
&#xD;
          -  Have abnormalities in lumbar spine as determined by the investigator&#xD;
&#xD;
          -  Have a history of clinically significant back pain and/or back injury&#xD;
&#xD;
          -  Have evidence or history of significant active bleeding or coagulation disorder&#xD;
&#xD;
          -  Have an allergy to lidocaine (XylocaineÂ®) or its derivatives&#xD;
&#xD;
          -  Have medical or surgical conditions in which LP is contraindicated The following&#xD;
             exclusion criterion applies only to those subjects enrolling in the part of the study&#xD;
             involving alcohol interaction Have an intolerance or allergy toward alcohol (symptoms&#xD;
             may include nausea, flushed face, vomiting, or hypotension) or who, in the opinion of&#xD;
             the investigator, may not be able to tolerate 0.8 gram per kilogram (g/kg) alcohol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

